Iron Overload and Iron-Chelation Therapy in Patients with Myelodysplastyc SyndromesLisette Del Corso, Eleonora Arboscello and Enrico Balleari*
Department of Hematology and Oncology; IRCCS AOU San Martino-IST, Genova, Italy
- *Corresponding Author:
- Enrico Balleari
Department of Hematology and Oncology; IRCCS AOU San Martino-IST
Largo R. Bensi 10, 16132 Genova, Italy
E-mail: [email protected]
Received date: September 20, 2013; Accepted date: November 14, 2013; Published date: November 20, 2013
Citation: Corso LD, Arboscello E, Balleari (2013) Iron Overload and Iron- Chelation Therapy in Patients with Myelodysplastyc Syndromes. J Blood Disord Transfus 5:175. doi: 10.4172/2155-9864.1000175
Copyright: © 2013 Lee Corso LD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Transfusion-dependency is an independent prognostic factor for survival in myelodysplastic syndromes (MDS). This negative impact is mainly due to the iron overload (IOL) consequent in large part to chronic transfusion therapy because of its detrimental effects on cardiac, hepatic and endocrine functions. The main tools useful for clinical diagnosis and monitoring of IOL should be serum ferritin, transferrin saturation and magnetic resonance imaging. If correctly evaluated, IOL is frequently observed in lower-risk MDS patients, and is more pronounced in longer surviving individuals. A detrimental role of IOL in MDS patients has been documented in several studies, showing a correlation with a shorter overall survival. Treatment of IOL with iron chelating therapy (ICT) has been shown to prevent at least in part these negative effects. The goal of ICT in MDS patients is to prevent and treat complications of IOL and to improve survival.